Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 13/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.79 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.79 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | HRH2 | P25021 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.79 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonidine SCHEMBL5983 | 0.89 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| SCHEMBL29374579 | 0.89 | ADRA2C (0.65) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| Clonidine SCHEMBL9838990 | 0.87 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| Clonidine SCHEMBL2231324 | 0.87 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| Clonidine SCHEMBL40752 | 0.87 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| Clonidine SCHEMBL613364 | 0.87 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| SCHEMBL9920135 | 0.82 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| SCHEMBL11176814 | 0.82 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| Clonidine SCHEMBL18050245 | 0.81 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CLMNAADRA1A | |
| SCHEMBL29352531 | 0.80 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CLMNAADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245314-A1 | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation | SHIONOGI INC. | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245314-A1 | Extended Release Formulation and Methods of Treating Adrenergic Dysregulation | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 5/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.